Reading Time: 16 minutes

Injectable formulations stand as a cornerstone of modern medicine, providing a powerful and precise means of delivering therapeutic agents to patients. This method of administration offers distinct advantages, particularly when rapid absorption is paramount, when the drug’s efficacy would be compromised by the digestive system (avoiding first-pass metabolism), or when ensuring patient adherence to the prescribed treatment regimen is crucial. The primary routes for injectable drug delivery encompass intravenous (IV) administration, where the drug is introduced directly into the bloodstream; subcutaneous (SC) injection, targeting the fatty tissue layer beneath the skin; intramuscular (IM) injection, delivering the drug into muscle tissue; and intradermal (ID) injection, which places the medication into the dermis, the middle layer of the skin.

Given the significant proportion of drugs formulated for administration via these injectable routes, the importance of thoroughly understanding a drug’s capabilities and behavior before progressing to human in vivo studies cannot be overstated. Pion’s innovative in vitro solutions are uniquely positioned to empower scientists in this critical endeavor, offering a comprehensive and holistic understanding of a drug’s potential, all while providing an accurate and ethical alternative to traditional animal models in the early stages of development.

The global market for injectable drugs is not only substantial but also exhibits robust and consistent growth, representing a significant opportunity within the pharmaceutical industry.¹ Projections from various market research reports underscore this upward trajectory. For instance, Veeva Life Sciences valued the global injectable drug market at USD 569.89 billion in 2024 and anticipates it reaching USD 820.05 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.55%.¹ The United States market, a major contributor, was estimated at USD 202.88 billion in 2024 and is expected to grow at a CAGR of 6.8% through 2034.¹

Notably, the Asia-Pacific region is poised to experience the most rapid expansion, with a projected CAGR of 8.7% between 2024 and 2029.¹ Another report by BioSpace, citing Coherent Market Insights, estimates the 2024 market at USD 586.1 billion, forecasting a surge to USD 984.1 billion by 2031, with a CAGR of 7.7%.² Within this market, oncology drugs are anticipated to exhibit the highest growth rate, with a CAGR of 9.1%.² MarketsandMarkets presents a slightly different perspective, valuing the global injectable drug delivery market at USD 697.9 billion in 2023 and projecting it to reach USD 1139.4 billion by 2029, with an 8.6% CAGR.³

Similarly, Precedence Research indicates a market size of USD 704.38 billion in 2024, forecasting an impressive USD 1609.29 billion by 2034, growing at a CAGR of 8.61%.⁵ In 2024, North America held the largest market share at 41%.⁵ Mordor Intelligence estimates the market at USD 612.92 billion in 2025, expecting it to reach USD 881.97 billion by 2030 at a CAGR of 7.55%, with large molecule drugs comprising a significant portion of the market.⁶ Focusing on delivery devices, Grandview Research valued the market at USD 467.53 billion in 2023 and projects growth to USD 823.29 billion by 2030, with an 8.7% CAGR; formulations held the dominant revenue share in 2023 at 57.9%.⁷ BioSpace, in another report, estimates the 2024 market at USD 757.06 billion, projecting USD 1,630.73 billion by 2033 with an 8.9% CAGR, noting North America’s leading position with a 51.9% share in 2023.⁹ ResearchAndMarkets.com provides an even more optimistic outlook, estimating the global market at USD 1 trillion in 2023 and forecasting USD 2 trillion by 2030, with a robust CAGR of 10.1%.¹⁰ Strategic Market Research reported the global injectable drug delivery market size as USD 615.87 billion in 2021, predicting a rise to USD 1677.91 billion by 2030, representing an 11.78% CAGR.¹¹ Finally, a separate press release from Grandview Research anticipates the injectable drug delivery devices market reaching USD 823.29 billion by 2030, with an 8.7% CAGR from 2024 to 2030.⁸ The global market for sterile injectable drugs was estimated at USD 732.0 billion in 2023 and is projected to reach USD 1.4 trillion by 2030, growing at a CAGR of 9.7%.¹²

This consistent and substantial growth across various segments of the injectable drug market underscores its increasing importance in the pharmaceutical landscape. Several factors contribute to this expansion, including the presence of robust healthcare systems, a growing patient population, increasing healthcare expenditure, and a rising incidence of chronic diseases.¹ Furthermore, the escalating demand for biopharmaceutical products, many of which necessitate parenteral administration due to their nature, is a significant driver of this market growth.² This trend highlights the crucial need for effective and efficient formulation development strategies tailored to the unique requirements of injectable drugs, particularly biologics.

To effectively formulate drugs for injectable administration, a thorough understanding of the different delivery routes is essential. Intravenous (IV) injection involves the direct introduction of medication into a vein, providing the most rapid onset of action and complete bioavailability.¹⁴ This route is critical in emergency situations, for precise dosing, for administering large volumes over time, and when oral administration is not feasible.¹⁶ IV therapy finds application in treating severe dehydration, delivering medications, providing pain relief, facilitating blood transfusions, and supplying essential nutrients.¹⁸ While offering the advantages of immediate action and bypassing first-pass metabolism, IV injections carry risks such as air embolism, vein collapse, fluid overload, hematoma, infection, infiltration, and phlebitis.¹⁴ Once an IV medication is administered, it cannot be retrieved, and errors in rapid injection can have serious consequences.¹⁴

Subcutaneous (SC) injection involves injecting medication into the fatty tissue layer located beneath the skin, resulting in a slower, more sustained absorption into the bloodstream.²¹ This route is often preferred for medications requiring gradual release and is convenient for patient self-administration at home.²¹ Common applications include the delivery of insulin for diabetes management, heparin for anticoagulation, hormone replacement therapies, certain vaccines, and various biologics.²¹ SC injections are generally easier to administer and less painful than intramuscular injections, offering a cost-effective option with a reduced risk of hospital-acquired infections compared to IV administration.²¹ However, the volume of medication that can be administered subcutaneously is limited (typically up to 1-2 ml), and the onset of action is slower than with IV injections.²¹ There is also a potential for localized tissue damage, such as lipodystrophy, and the absorption rate can vary depending on the injection site and individual patient factors.²¹

Intramuscular (IM) injection delivers medication deep into the muscle tissue, which boasts a rich blood supply, facilitating faster absorption compared to subcutaneous or intradermal routes.²⁸ This method bypasses first-pass metabolism and is frequently employed for administering vaccines, antibiotics, hormones, and long-acting formulations.²⁸ IM injections offer the advantages of rapid and effective drug assimilation, along with the capacity to administer larger volumes of medication compared to subcutaneous injections.²⁸ Nevertheless, this route necessitates proper anatomical knowledge and technique to avoid the risk of hitting blood vessels or nerves, and the injection itself can be painful.²⁹ Self-administration of IM injections can also prove challenging for some patients.²⁹

Intradermal (ID) injection involves the administration of a small volume of medication into the dermis, the layer of skin situated just beneath the epidermis.³⁸ This route is characterized by the slowest absorption rate among the injectable methods and is primarily utilized for diagnostic tests, such as tuberculosis skin tests and allergy testing, as well as for the administration of certain vaccines.²⁴ A key advantage of ID injections is that the localized reaction is easily visible, allowing for the assessment of the degree of response.³⁸ In vaccination, this route can potentially elicit an improved immune response with lower antigen doses.⁴⁰ However, intradermal injection demands specialized training and precise technique, and traditional methods can suffer from poor reproducibility.⁴⁰ The volume of medication that can be administered via this route is limited, and it may not be the preferred choice for life-saving drugs requiring frequent self-injection.⁴³

Also Read: Revolutionizing Injectable Formulation Delivery: Ethical Alternatives for Accurate Insights

The development of injectable formulations is fraught with challenges that pharmaceutical scientists must carefully navigate. Maintaining drug stability is paramount, as these products are administered directly into the body. Injectable solutions must be sterile, exhibit low pyrogen levels, and adhere to stringent compendial specifications throughout their intended shelf life.⁴⁵ Stability encompasses various aspects, including chemical (no significant degradation of the active ingredient), physical (no changes in appearance or precipitation), microbiological (sterility maintained), therapeutic (intended effect remains), and toxicological (no harmful degradation products form).⁴⁷ Degradation can be triggered by a multitude of factors, such as temperature, pH, humidity, light exposure, hydrolysis, oxidation, and protein aggregation.⁴⁷ Formulation-related elements like pH, buffer system, excipients, and the type of solvent play a crucial role in stability, as does the choice of packaging material and environmental storage conditions.⁴⁷ High-concentration protein and monoclonal antibody formulations, often required for subcutaneous delivery to limit injection volume, face particular challenges concerning viscosity and stability, especially the propensity for aggregation.⁵⁰ Biopharmaceutical drugs, due to their complex structures, are inherently more susceptible to instability.⁴⁸

Another significant hurdle is addressing solubility issues. A considerable number of new drug candidates exhibit poor aqueous solubility, which can severely impede formulation development and lead to low bioavailability.⁵² Insufficient solubility can result in suboptimal drug delivery and absorption, ultimately compromising the therapeutic effectiveness of the injectable product and potentially causing adverse effects.⁵⁶ To overcome this challenge, formulation scientists employ a range of techniques aimed at enhancing drug solubility. These include physical modifications like particle size reduction and crystal engineering, as well as chemical modifications such as salt formation, complexation with cyclodextrins, the use of surfactants, and the creation of solid dispersions.⁵² Lipid-based formulations and amorphous solid dispersion technologies have also emerged as effective strategies for improving the solubility and bioavailability of poorly soluble active pharmaceutical ingredients (APIs).⁵² Furthermore, the development of next-generation parenteral excipients, such as polymeric micelles, offers promising avenues for enhancing the solubility of challenging molecules, particularly in the field of oncology therapeutics.⁵⁵

Ensuring optimal bioavailability after injection is critical for achieving the desired therapeutic outcome. Bioavailability refers to the rate and extent to which the active form of the drug reaches the systemic circulation.⁶⁰ The very act of injecting a drug can impose various stresses that influence its subsequent bioavailability.⁶³

A drug’s pharmacokinetic (PK) properties, encompassing absorption, distribution, metabolism, and excretion, are fundamental determinants of its bioavailability.⁶⁴ Poor solubility and a slow dissolution rate are significant drug-related factors that can limit bioavailability.⁵² Therefore, formulation strategies often focus on improving the drug’s dissolution rate and maintaining a supersaturated state to facilitate absorption.⁶⁷ Bioavailability is influenced by a complex interplay of factors, including the drug’s inherent physicochemical properties, the specific route of administration chosen, and various physiological barriers within the body.⁶²

Finally, maintaining sterility in injectable formulations is of paramount importance. Because these drugs bypass the body’s natural protective barriers and are introduced directly into the internal environment, they must be completely free of viable microorganisms.³⁷ Any contamination can lead to severe health risks, including infections and sepsis.⁶⁹ The manufacturing of sterile injectables requires strict adherence to aseptic processing techniques or the implementation of terminal sterilization methods.³⁷ This necessitates maintaining a highly controlled environment throughout the entire production process, from the initial handling of sterile raw materials to the final stages of sterile packaging.³⁷ The pharmaceutical industry is subject to stringent regulatory requirements imposed by authorities like the FDA to ensure that all sterile injectable products meet the highest standards of quality and safety.³⁷

The efficacy of injectable drug formulations is intricately linked to their pharmacokinetic (PK) and pharmacodynamic (PD) properties. PK describes the journey of the drug through the body, detailing its absorption, distribution, metabolism, and excretion, while PD elucidates how the drug exerts its effects on the body, including its mechanism of action and the resulting therapeutic outcomes.⁶⁴ A comprehensive understanding of this PK/PD relationship is crucial for determining the optimal dosage of an injectable drug and minimizing the risk of toxicity.⁷⁴ PK/PD studies play a vital role in establishing appropriate dosing regimens, selecting the most effective route of administration, and defining the necessary duration of drug exposure to achieve the desired therapeutic effect.⁷⁷ Regulatory bodies such as the FDA mandate thorough PK/PD investigations as part of the drug approval process.⁷⁴

Furthermore, PK/PD modeling techniques allow scientists to dissect the contributions of drug-specific, delivery system-specific, and physiological system-specific parameters, leading to a deeper understanding of complex drug delivery systems.⁷⁵ Bioavailability, a critical PK parameter, directly influences the concentration of the drug at its target site and, consequently, its pharmacodynamic effect.⁶⁰

To truly understand how an injectable formulation will perform in the body, it is essential to simulate the injection environment in vitro. Subcutaneous injection, in particular, exposes the drug product to a variety of stresses that can significantly influence its bioavailability.⁶³

These stresses encompass chemical factors, such as alterations in buffer composition, pH changes, and the potential loss of excipients, as well as physical factors, including temperature and pressure fluctuations at the injection site.⁶³

Pion’s innovative solutions are specifically engineered to replicate these complex stress conditions and environmental transitions in a laboratory setting, enabling scientists to meticulously study their impact on drug formulations.⁶³ This in vitro approach provides a controlled and ethical means to gain critical insights into drug behavior without relying on animal models in the early stages of development.

Upon subcutaneous injection, drugs can also encounter non-specific interactions with the extracellular matrix (ECM), a complex network of proteins and other molecules that surrounds cells in tissues. Additionally, there is a potential for the drug itself, particularly biopharmaceuticals like proteins and peptides, to undergo aggregation events.⁶³

Protein aggregation can have detrimental effects, including limiting the drug’s solubility, increasing its viscosity, leading to the formation of degradation products, and potentially triggering unwanted immune responses in patients.⁸² To mitigate these risks, formulation scientists often incorporate surfactants, stabilizers, and other excipients into injectable products to prevent or minimize protein aggregation.⁸² Pion’s in vitro simulation technologies, most notably the SCISSOR N3 Injection Site Simulator, are specifically designed to allow researchers to investigate these intricate interactions with an artificial ECM and to closely monitor for any signs of aggregation events.⁶³ This capability provides invaluable information for the rational design and optimization of subcutaneous injectable formulations.

Pion Company offers a suite of cutting-edge solutions to address the complexities of injectable formulation analysis. The SCISSOR N3 Injection Site Simulator stands as a testament to Pion’s commitment to innovation in this field. This instrument is meticulously engineered to accurately mimic the physiological properties of subcutaneous tissue in vitro, providing a robust platform for investigating the release performance of subcutaneous formulations under conditions that closely resemble the human body.⁸⁹ The SCISSOR N3 allows for the simulation of both chemical and physical stresses that a drug product encounters upon injection, as well as the crucial interactions with the extracellular matrix.⁶³ The system’s design enables the simultaneous execution of up to three independent assays, significantly enhancing throughput.⁹⁰ Integrated with cameras and turbidity sensors, the SCISSOR N3 facilitates the effective detection of turbidity, providing valuable insights into potential precipitation or dissolution events within the formulation.⁹¹ Furthermore, it features a dedicated fiber optic probe port, enabling seamless integration with the Rainbow R6 Concentration Monitor for real-time monitoring of drug concentration at the simulated injection site.⁹⁰ The SCISSOR N3 also incorporates the capability to track pH changes at the injection site, offering critical information about the local microenvironment.⁸⁹

The Rainbow R6 for QC and R&D (Dissolution) is another key component of Pion’s offerings for injectable formulation analysis. This in-situ fiber optic UV-Vis spectrometer provides real-time concentration monitoring, a capability essential for characterizing both the compound itself and its formulation.⁹² The Rainbow R6 is a versatile analytical instrument employed for a wide range of applications, including dissolution testing, flux assays, solubility studies, and other analyses demanding high accuracy and repeatability in concentration measurements, even in complex media.⁹⁵ Equipped with up to eight independent fiber optic channels, the Rainbow R6 allows for the simultaneous analysis of multiple samples or experimental conditions.⁹² Its real-time concentration data output enables the generation of detailed dissolution and release profiles, which are indispensable for understanding the behavior of injectable drugs.⁹³ Notably, the Rainbow R6 can be directly coupled with the SCISSOR N3, providing a powerful platform for in-situ concentration monitoring within the simulated subcutaneous injection environment.⁹⁰

Pion also provides a comprehensive range of Laboratory BEE High Pressure Homogenizers and their pilot and industrial scale counterparts. These homogenizers are vital tools in the formulation of stable emulsions, dispersions, and suspensions, which are fundamental to many injectable drug products.¹⁰⁰ High-pressure homogenization effectively reduces the particle size of the drug substance, improves the uniformity of mixing, and ensures a consistent distribution of the active pharmaceutical ingredient throughout the formulation.¹⁰⁰ These attributes are critical for achieving optimal bioavailability and ensuring the long-term stability of the injectable product.¹⁰⁰ Additionally, Pion’s high-pressure homogenizers can be utilized for cell lysis, a process essential for the extraction of intracellular components in the development of certain biopharmaceutical injectables.¹⁰⁰ The availability of these homogenizers across different scales, from laboratory research to pilot-scale development and industrial manufacturing, facilitates a seamless transition throughout the drug development lifecycle.¹⁰¹

Pion Company is committed to the ethical advancement of drug development. Their innovative solutions provide an accurate and reliable alternative to traditional animal models, particularly in the early stages of injectable drug development.

In vitro simulation technologies, such as the SCISSOR N3, have demonstrated their ability to accurately predict the in vivo behavior of injectable formulations by effectively mimicking the relevant physiological conditions and stresses.⁷⁵ By leveraging these in vitro methods, pharmaceutical scientists can gain crucial insights into drug release, stability, and interactions with the biological environment without the need for animal experimentation, aligning with growing ethical concerns and the increasing regulatory emphasis on reducing animal use in research.¹⁰⁰ This approach not only addresses ethical considerations but also has the potential to significantly expedite the drug development process by enabling faster and more cost-effective screening and optimization of formulations compared to traditional in vivo studies.¹⁰²

In conclusion, making informed decisions early in the development of injectable formulations is paramount for success. Pion Company offers a suite of cutting-edge solutions, including the SCISSOR N3 Injection Site Simulator, the Rainbow R6 for real-time concentration monitoring, and a range of high-pressure homogenizers, that directly address the key challenges inherent in injectable drug development. These technologies provide scientists with a comprehensive understanding of a drug’s capabilities in vitro, allowing for accurate prediction of in vivo behavior and the selection of optimal formulations. By choosing Pion’s innovative tools, pharmaceutical researchers can not only accelerate their development timelines and improve the success rate of their injectable products but also contribute to a more ethical and responsible approach to drug discovery by significantly reducing the reliance on animal models. Contact Pion today to discover how their advanced in vitro solutions can revolutionize your injectable formulation development process and help you bring life-saving medications to patients more efficiently and ethically.

Works cited

1. Injectable Market Growth: A Multi-Billion-Dollar Opportunity – Veeda Clinical Research, accessed May 2, 2025, https://veedalifesciences.com/injectable-market-growth-a-multi-billion-dollar-opportunity/
2. Sterile Injectables Market Size to Worth USD 984.1 Billion By 2031 – BioSpace, accessed May 2, 2025, https://www.biospace.com/press-releases/sterile-injectables-market-size-to-worth-usd-984-1-billion-by-2031
3. Injectable Drug Delivery Market Growth, Drivers, and Opportunities – MarketsandMarkets, accessed May 2, 2025, https://www.marketsandmarkets.com/Market-Reports/injectable-drug-delivery-market-150.html
4. Injectable drug delivery market to value $1139.4b by 2029, accessed May 2, 2025, https://www.europeanpharmaceuticalreview.com/news/228415/injectable-drug-delivery-market-to-value-1139-4b-by-2029/
5. Injectable Drug Delivery Market Size to Hit USD 1609.29 Bn by 2034, accessed May 2, 2025, https://www.precedenceresearch.com/injectable-drugs-delivery-market
6. Injectable Drugs Market – Size, Share & Industry Analysis – Mordor Intelligence, accessed May 2, 2025, https://www.mordorintelligence.com/industry-reports/sterile-injectable-drugs-market
7. Injectable Drug Delivery Devices Market Size Report, 2030 – Grand View Research, accessed May 2, 2025, https://www.grandviewresearch.com/industry-analysis/injectable-drug-delivery-devices-industry
8. Injectable Drug Delivery Devices Market To Reach $823.29Bn By 2030, accessed May 2, 2025, https://www.grandviewresearch.com/press-release/global-injectable-drug-delivery-market
9. Injectable Drug Delivery Market Size to Hit USD 1,630.73 Bn by 2033 – BioSpace, accessed May 2, 2025, https://www.biospace.com/injectable-drug-delivery-market-size-to-hit-usd-1-630-73-bn-by-2033
10. Injectable Drugs Delivery Business Research Report 2024: Market to Grow by $1 Trillion from 2023 to 2030, Driven by Rising Demand for Targeted Therapies and Injectable Drug Delivery in Oncology – ResearchAndMarkets.com – Business Wire, accessed May 2, 2025, https://www.businesswire.com/news/home/20241015828815/en/Injectable-Drugs-Delivery-Business-Research-Report-2024-Market-to-Grow-by-%241-Trillion-from-2023-to-2030-Driven-by-Rising-Demand-for-Targeted-Therapies-and-Injectable-Drug-Delivery-in-Oncology—ResearchAndMarkets.com
11. Injectable Drugs Delivery Market Size ($1677.91 Billion) 2030 – Strategic Market Research, accessed May 2, 2025, https://www.strategicmarketresearch.com/market-report/injectable-drug-delivery-market
12. Sterile Injectable Drugs Strategic Market Research Report 2024 – GlobeNewswire, accessed May 2, 2025, https://www.globenewswire.com/news-release/2024/11/06/2975894/28124/en/Sterile-Injectable-Drugs-Strategic-Market-Research-Report-2024-Global-Market-to-Reach-1-4-Trillion-by-2030-Biosimilars-Gain-Traction-Opening-New-Opportunities.html
13. What Are The Key Trends And Developments In Injectable Drug Formulation And Delivery, accessed May 2, 2025, https://www.outsourcedpharma.com/doc/what-are-the-key-trends-and-developments-in-injectable-drug-formulation-and-delivery-0001
14. Table 2.2b, [IV Push Medication Advantages and Disadvantages[7]]. – Nursing Advanced Skills – NCBI, accessed May 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK594489/table/ch2medications.T.iv_push_medication_adva/
15. Chapter 2 Administer IV Push Medications – Nursing Advanced Skills – NCBI Bookshelf, accessed May 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK594489/
16. Intravenous injection: Uses, equipment, sites, and more – Medical News Today, accessed May 2, 2025, https://www.medicalnewstoday.com/articles/intravenous-injection
17. Intravenous Medication Administration: What to Know – Healthline, accessed May 2, 2025, https://www.healthline.com/health/intravenous-medication-administration-what-to-know
18. IV Fluids (Intravenous Fluids): Types & Uses – Cleveland Clinic, accessed May 2, 2025, https://my.clevelandclinic.org/health/treatments/21635-iv-fluids
19. IV therapy: Uses, benefits, risks, and more – Medical News Today, accessed May 2, 2025, https://www.medicalnewstoday.com/articles/iv-therapy
20. The Pros and Cons of IV Infusions: What You Need to Know – Elysian Beauty & Wellness, accessed May 2, 2025, https://elysianwellnessbeauty.com/the-pros-and-cons-of-iv-infusions-what-you-need-to-know/
21. Subcutaneous Administration – Nurseslabs, accessed May 2, 2025, https://nurseslabs.com/subcutaneous-administration/
22. Subcutaneous administration – Wikipedia, accessed May 2, 2025, https://en.wikipedia.org/wiki/Subcutaneous_administration
23. Subcutaneous Injection: Definition and Patient Education – Healthline, accessed May 2, 2025, https://www.healthline.com/health/subcutaneous-injection
24. 7.3 Intradermal and Subcutaneous Injections – Clinical Procedures for Safer Patient Care, accessed May 2, 2025, https://opentextbc.ca/clinicalskills/chapter/6-7-intradermal-subcutaneous-and-intramuscular-injections/
25. Types of injections: Uses, sites, and what to expect – Medical News Today, accessed May 2, 2025, https://www.medicalnewstoday.com/articles/types-of-injections
26. Advantages of Subcutaneous Drug Delivery Benefits | Enable Injections, accessed May 2, 2025, https://enableinjections.com/advantages-of-subcutaneous-drug-delivery/
27. Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site – PMC, accessed May 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6822791/
28. Disadvantages of different types of injection – YuBoost, accessed May 2, 2025, https://yuboost.com/en/expertise/what-are-the-advantages-of-the-different-types-of-injection/
29. Intramuscular Injection: Sites, Techniques, and Tips – Simple Nursing, accessed May 2, 2025, https://simplenursing.com/intramuscular-injection/
30. Intramuscular injection – Wikipedia, accessed May 2, 2025, https://en.wikipedia.org/wiki/Intramuscular_injection
31. Intramuscular Injections VS. Traditional Medication: A Comparison – Hope For Healing, accessed May 2, 2025, https://get2theroot.com/intramuscular-injections-vs-traditional-medication-a-comparison/
32. Intramuscular Injection – StatPearls – NCBI Bookshelf, accessed May 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK556121/
33. Intramuscular injections – Knowledge and References – Taylor & Francis, accessed May 2, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmacy_and_dispensing/Intramuscular_injections/
34. Intramuscular injection: Locations and administration – Medical News Today, accessed May 2, 2025, https://www.medicalnewstoday.com/articles/323115
35. Intramuscular Injection: Definition and Patient Education – Healthline, accessed May 2, 2025, https://www.healthline.com/health/intramuscular-injection
36. The Science Behind Intramuscular Injections: How They Work – Hope For Healing, accessed May 2, 2025, https://get2theroot.com/the-science-behind-intramuscular-injections-how-they-work/
37. Sterile Injectable CDMOs: A Comprehensive Guide to Trends and Best Practices, accessed May 2, 2025, https://pharmasource.global/content/guides/category-guide/sterile-injectable-cdmos-a-comprehensive-guide-to-trends-and-best-practices/
38. Intradermal Injection: How and When to Administer – Simple Nursing, accessed May 2, 2025, https://simplenursing.com/intradermal-injection/
39. Intradermal injection- Introduction, procedure,complications | PPT – SlideShare, accessed May 2, 2025, https://www.slideshare.net/slideshow/intradermal-injection-introduction-procedurecomplications/235979847
40. Intradermal injection I VAX-ID offers a reliable and easy solution – Idevax, accessed May 2, 2025, https://idevax.com/applications/intradermal-injection/
41. Intradermal vaccination for infants and children – PMC, accessed May 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5027705/
42. Intradermal delivery of vaccines: potential benefits and current challenges – PMC, accessed May 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3044245/
43. New Technology Brings Simplicity & Scalability to Intradermal Drug Delivery, accessed May 2, 2025, https://drug-dev.com/intradermal-delivery-new-technology-brings-simplicity-scalability-to-intradermal-drug-delivery/
44. Guide to Different Types of Vaccine Injections, accessed May 2, 2025, https://www.myvaccinelawyer.com/vaccine-injury-lawyer/resources/vaccine/injection-types
45. Considerations in Formulation Development of Injectable Solutions, accessed May 2, 2025, https://drug-dev.com/formulation-forum-considerations-in-formulation-development-of-injectable-solutions/
46. Considerations In Formulation Development Of Injectable Solutions – Drug Delivery Leader, accessed May 2, 2025, https://www.drugdeliveryleader.com/doc/considerations-in-formulation-development-of-injectable-solutions-0001
47. Understanding the Stability of Injectable Products | Pharmaceutical Guidelines, accessed May 2, 2025, https://www.pharmaguideline.com/2025/04/understanding-stability-of-injectable-products.html
48. Parenteral Drugs: Formulation Requirements and Common Challenges – Pharma Now, accessed May 2, 2025, https://www.pharmanow.live/knowledge-hub/innovation/parenteral-drugs-formulation-challenges
49. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies – PMC – PubMed Central, accessed May 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4455970/
50. Overcoming Challenges to High-Concentration Formulation Development, accessed May 2, 2025, https://www.pharmasalmanac.com/articles/overcoming-challenges-to-high-concentration-formulation-development
51. Overcoming Challenges Associated with Biologic Drug Formulation & Development, accessed May 2, 2025, https://www.westpharma.com/blog/2019/april/overcoming-challenges-biologic-drug-formulation-development
52. SPECIAL FEATURE – Solubility & Bioavailability: Difficult Beasts to Tame, accessed May 2, 2025, https://drug-dev.com/special-feature-solubility-bioavailability-difficult-beasts-to-tame/
53. Drug Solubility: Importance and Enhancement Techniques – PMC, accessed May 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3399483/
54. Insoluble drug delivery strategies: review of recent advances and business prospects – PMC, accessed May 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4629443/
55. Solving parenteral solubility challenges in the development of oncology therapeutics, accessed May 2, 2025, https://www.lubrizol.com/Health/Blog/2023/06/Solving-parenteral-solubility-challenges-in-the-development-of-oncology-therapeutics
56. Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics – PMC – PubMed Central, accessed May 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9495787/
57. 4 Factors Affecting Solubility of Drugs – Ascendia Pharmaceutical Solutions, accessed May 2, 2025, https://ascendiacdmo.com/newsroom/2021/07/05/factors-affecting-drug-solubility
58. Overcoming Solubility Challenges: Techniques To Improve Dissolution Rate And Increase Bioavailability – Agno Pharma, accessed May 2, 2025, https://agnopharma.com/blog/overcoming-solubility-challenges-techniques-to-improve-dissolution-rate-and-increase-bioavailability/
59. How Lipid Nanoparticles Overcome Solubility Challenges For Oral And Injectable Formulations – Drug Delivery Leader, accessed May 2, 2025, https://www.drugdeliveryleader.com/doc/how-lipid-nanoparticles-overcome-solubility-challenges-for-oral-and-injectable-formulations-0001
60. Bioavailability – Wikipedia, accessed May 2, 2025, https://en.wikipedia.org/wiki/Bioavailability
61. Drug Bioavailability – StatPearls – NCBI Bookshelf, accessed May 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557852/
62. The Bioavailability of Drugs—The Current State of Knowledge – MDPI, accessed May 2, 2025, https://www.mdpi.com/1420-3049/28/24/8038
63. Injectable Formulation Delivery | Pion, Inc., accessed May 2, 2025, https://www.pion-inc.com/solutions/applications/injectable-formulation-delivery
64. Chapter 1 Pharmacokinetics & Pharmacodynamics – Nursing Pharmacology – NCBI, accessed May 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK595006/
65. Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems – PMC, accessed May 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6806371/
66. The Importance of Pharmacokinetics in Pharmacological Therapy., accessed May 2, 2025, https://www.jbclinpharm.org/articles/the-importance-of-pharmacokinetics-in-pharmacological-therapy-12173.html
67. Overcoming Bioavailability Challenges In Oral Formulation Development – pharm-int, accessed May 2, 2025, https://www.pharm-int.com/resources/overcoming-bioavailability-challenges-in-oral-formulation-development/
68. Vidhya M. Bioavailability – Challenges and Advances in Drug Targeting. Bioequiv & Bioavailab Int J 2023, 7(1) – Medwin Publishers, accessed May 2, 2025, https://medwinpublishers.com/BEBA/bioavailability-challenges-and-advances-in-drug-targeting.pdf
69. Understanding Sterile Injectables: Key Considerations for the Pharmaceutical Industry, accessed May 2, 2025, https://adragos-pharma.com/understanding-sterile-injectables-key-considerations-for-the-pharmaceutical-industry/
70. What is a Sterile Injectable and How Are They Made? – ten23 health, accessed May 2, 2025, https://www.ten23.health/blog/what-is-a-sterile-injectable-and-how-are-they-made
71. Sterile injectables: What they are and how they’re manufactured – Vetter Pharma, accessed May 2, 2025, https://www.vetter-pharma.com/en/cdmo-insights/sterile-injectables/
72. Ensuring Sterility and Quality: A Deep Dive into Aseptic Manufacturing of Pharmaceutical Injectable Products – Lighthouse Worldwide Solutions, accessed May 2, 2025, https://www.golighthouse.com/en/blog/sterile-pharmaceutical-injectable-products-manufacturing/
73. Does your dosage form need to be sterile? Key differences between sterile and non-sterile dosage forms – Vici Health Sciences, accessed May 2, 2025, https://vicihealthsciences.com/does-your-dosage-form-need-to-be-sterile-key-differences-between-sterile-and-non-sterile-dosage-forms/
74. The importance of pharmacokinetics, pharmacodynamics in pharmacy – UBNow: News and views for UB faculty and staff, accessed May 2, 2025, https://www.buffalo.edu/ubnow/stories/2025/03/qa-jusko-pk-pd.html
75. Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges – Frontiers, accessed May 2, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.00997/full
76. Pharmacokinetic and pharmacodynamic relationships – Pharmaceutical Press, accessed May 2, 2025, https://www.pharmaceuticalpress.com/resources/article/pharmacokinetic-and-pharmacodynamic-relationships/
77. Pharmacometrics, PK & PD: Key Drug Development Tools – Allucent, accessed May 2, 2025, https://www.allucent.com/solutions/clinical-pharmacology/clinical-modeling-simulation/pharmacokinetics-and-pharmacodynamics-pkpd
78. Consideration of Pharmacokinetic Pharmacodynamic Relationships in the Discovery of New Pain Drugs – NCBI, accessed May 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK57267/
79. Introduction to Pharmacokinetics and Pharmacodynamics – ASHP, accessed May 2, 2025, https://www.ashp.org/-/media/store%20files/p2418-sample-chapter-1.pdf
80. Understanding Pharmacokinetics & Pharmacodynamics – Alimentiv, accessed May 2, 2025, https://alimentiv.com/pharmacokinetics-vs-pharmacodynamics/
81. iJOBS Primer: What You Need to Know about PK/PD for a Job in Pharma, accessed May 2, 2025, https://grad.rutgers.edu/news/ijobs-primer-what-you-need-know-about-pkpd-job-pharma
82. Solutions for Protein Aggregation in Biologics Formulations – Pfanstiehl, accessed May 2, 2025, https://pfanstiehl.com/en/solutions/protein-aggregation-reduction/
83. Use of Stabilizers and Surfactants to Prevent Protein Aggregation – Sigma-Aldrich, accessed May 2, 2025, https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/pharmaceutical-and-biopharmaceutical-manufacturing/downstream-processing/stabilizers-and-surfactants-to-prevent-protein-aggregation
84. How to Prevent Protein Aggregation through Stabilizers and Surfactants – Sigma-Aldrich, accessed May 2, 2025, https://www.sigmaaldrich.com/US/en/collections/webinars/prevent-protein-aggregation
85. Optimizing Excipient Properties to Prevent Aggregation in Biopharmaceutical Formulations – PMC – PubMed Central, accessed May 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10777730/
86. Protein Aggregation and Immunogenicity of Biotherapeutics – PMC – PubMed Central, accessed May 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7362938/
87. Novel Formulations for Non-Invasive Delivery & Stabilization of Peptides, accessed May 2, 2025, https://drug-dev.com/formulating-peptides-novel-formulations-for-non-invasive-delivery-stabilization-of-peptides/
88. Advancements in hydrogel formats to model potential drug interactions occurring at the subcutaneous injection site – Pion Inc, accessed May 2, 2025, https://www.pion-inc.com/resources/advancements-in-hydrogel-formats-to-model-potential-drug-interactions-occurring-at-the-subcutaneous-injection-site
89. Analytical Services: in vitro Subcutaneous Injection Site Simulation, accessed May 2, 2025, https://cdn.prod.website-files.com/644d2ffb3f7ec1eca95b44dd/66e9e0b5cb4de0c8b276c60c_WEB%20ANALYTICAL%20SERVICES%20FLYER%202%20PAGER.pdf
90. SCISSOR N3 SubCutaneous Injection Site Simulator – Rackcdn.com, accessed May 2, 2025, https://7157e75ac0509b6a8f5c-5b19c577d01b9ccfe75d2f9e4b17ab55.ssl.cf1.rackcdn.com/EAACNKPE-PDF-4-451365-4439746172.pdf
91. SubCutaneous Injection Site SimulatOR (SCISSOR) N3 Solution for Subcutaneous Formulations, accessed May 2, 2025, https://cdn.prod.website-files.com/644d2ffb3f7ec1eca95b44dd/64794ba73c74470c157c7c61_Scissor%20N3%20Product%20Sheet_FINAL_updated%20May%202022.pdf
92. Rainbow R6 Concentration Monitor – Paralab, accessed May 2, 2025, https://paralab.es/wp-content/uploads/2023/01/Rainbow-R6-poduct-sheet-June-2022.pdf
93. Rainbow 6 – BTF-Pion-Scientific-Instruments-France, accessed May 2, 2025, https://btf-pion-scientific-instrument.constantcontactsites.com/rainbow-6
94. Rainbow R6 Multi-channel fiber optic UV-VIS Spectrophotometer – Select Science, accessed May 2, 2025, https://www.selectscience.net/product/rainbow-r6-multi-channel-fiber-optic-uv-vis-spectrophotometer
95. Rainbow R6 for QC and R&D – Pion Inc, accessed May 2, 2025, https://www.pion-inc.com/solutions/products/rainbow-r6
96. Rainbow R6 Fiber Optic UV Concentration Monitor Product Sheet – Pion Inc, accessed May 2, 2025, https://www.pion-inc.com/resources/rainbow-r6-product-sheet
97. Rainbow R6 Concentration Monitor, accessed May 2, 2025, https://assets-global.website-files.com/644d2ffb3f7ec1eca95b44dd/64ef5490b10747345be2892e_web-rainbow-r6-concentration-monitor-revised-june-2023.pdf
98. Rainbow R6 In-Situ Fiber Optic UV-Vis Spectrometer – 上海埃飞科技, accessed May 2, 2025, http://www.worldwide-china.com/en/productDetails.php?serial=284
99. The Pion Inc. Rainbow R6 UV-Vis Dynamic Dissolution Monitor System – YouTube, accessed May 2, 2025, https://www.youtube.com/watch?v=MJWRYt9nrbA
100. FAQs – Pion Inc, accessed May 2, 2025, https://www.pion-inc.com/faqs
101. The Benefits of a Laboratory Homogenizer For Cell Lysis – Pion Inc, accessed May 2, 2025, https://www.pion-inc.com/blog/the-benefits-of-a-laboratory-homogenizer-for-cell-lysis
102. Predicting In Vivo Efficacy from In Vitro Data: Quantitative Systems Pharmacology Modeling for an Epigenetic Modifier Drug in Cancer – PubMed Central, accessed May 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7070804/
103. An In Vitro–In Vivo Simulation Approach for the Prediction of Bioequivalence – MDPI, accessed May 2, 2025, https://www.mdpi.com/1996-1944/14/3/555

The history of SCISSOR, Subcutaneous Injection Site Simulator | Pion Inc. – YouTube, accessed May 2, 2025, https://www.youtube.com/watch?v=DYbasRJYjuw